CSCR
MCID: CNT060
MIFTS: 38

Central Serous Chorioretinopathy (CSCR)

Categories: Bone diseases, Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Central Serous Chorioretinopathy

MalaCards integrated aliases for Central Serous Chorioretinopathy:

Name: Central Serous Chorioretinopathy 52 58 71
Central Serous Chorioretinopathy After Bone Marrow Transplantation 52
Central Serous Choroidopathy 52
Cscr 58

Characteristics:

Orphanet epidemiological data:

58
central serous chorioretinopathy
Inheritance: Not applicable;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

ICD10 via Orphanet 33 H35.7
UMLS via Orphanet 72 C0730328
Orphanet 58 ORPHA443079
UMLS 71 C0730328

Summaries for Central Serous Chorioretinopathy

NIH Rare Diseases : 52 Central serous chorioretinopathy is a disease that causes fluid to build up under the retina , the back part of the inner eye that sends sight information to the brain. The fluid leaks from the choroid (the blood vessel layer under the retina). The cause of this condition is unknown but stress can be a risk factor . Signs and symptoms include dim and blurred blind spot in the center of vision, distortion of straight lines and seeing objects as smaller or farther away. Many cases of central serous chorioretinopathy improve without treatment after 1-2 months. Laser treatment may be an option for other individuals.

MalaCards based summary : Central Serous Chorioretinopathy, also known as central serous chorioretinopathy after bone marrow transplantation, is related to choroiditis and kuhnt-junius degeneration. An important gene associated with Central Serous Chorioretinopathy is CFH (Complement Factor H), and among its related pathways/superpathways are Complement and coagulation cascades and Cell adhesion_ECM remodeling. The drugs Verteporfin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone.

Related Diseases for Central Serous Chorioretinopathy

Diseases related to Central Serous Chorioretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.2 CFH ARMS2
2 kuhnt-junius degeneration 30.8 CFH ARMS2
3 multifocal choroiditis 30.7 CFH ARMS2
4 macular degeneration, age-related, 1 30.7 CFH C4B ARMS2
5 angioid streaks 30.4 CFH ARMS2
6 antiphospholipid syndrome 30.0 SERPINE1 PLAT CFH
7 bestrophinopathy, autosomal recessive 11.8
8 retinal detachment 11.2
9 microvascular complications of diabetes 5 10.8
10 scotoma 10.7
11 macular retinal edema 10.7
12 periodontal ehlers-danlos syndrome 10.6
13 sleep apnea 10.6
14 uveitis 10.6
15 retinal disease 10.6
16 helicobacter pylori infection 10.5
17 vogt-koyanagi-harada disease 10.5
18 refractive error 10.5
19 hydrops, lactic acidosis, and sideroblastic anemia 10.5
20 eye disease 10.5
21 retinal vascular disease 10.5
22 retinal degeneration 10.5
23 yemenite deaf-blind hypopigmentation syndrome 10.4
24 neuroretinitis 10.4
25 myopia 10.4
26 conn's syndrome 10.4
27 neuritis 10.4
28 retinitis 10.4
29 coronary heart disease 1 10.4
30 impotence 10.4
31 ulcerative colitis 10.4
32 optic nerve disease 10.3
33 hemangioma 10.3
34 sleep disorder 10.3
35 peptic ulcer disease 10.3
36 cataract 10.3
37 lupus erythematosus 10.3
38 multiple sclerosis 10.3
39 colitis 10.3
40 optic neuritis 10.3
41 posterior uveitis 10.3
42 telangiectasis 10.3
43 color blindness 10.3
44 acute retrobulbar neuritis 10.3
45 retinal vein occlusion 10.3
46 melanoma 10.3
47 adenoma 10.3
48 vasculitis 10.3
49 neuropathy 10.3
50 47,xyy 10.3

Graphical network of the top 20 diseases related to Central Serous Chorioretinopathy:



Diseases related to Central Serous Chorioretinopathy

Symptoms & Phenotypes for Central Serous Chorioretinopathy

Drugs & Therapeutics for Central Serous Chorioretinopathy

Drugs for Central Serous Chorioretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verteporfin Approved, Investigational Phase 4 129497-78-5
2
Bevacizumab Approved, Investigational Phase 4 216974-75-3
3
Ranibizumab Approved Phase 4 347396-82-1 459903
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Eplerenone Approved Phase 4 107724-20-9 150310 443872
7 Dermatologic Agents Phase 4
8 Photosensitizing Agents Phase 4
9 Endothelial Growth Factors Phase 4
10 Angiogenesis Inhibitors Phase 4
11 Antineoplastic Agents, Immunological Phase 4
12 Mitogens Phase 4
13 Hormone Antagonists Phase 4
14 Hormones Phase 4
15 Immunologic Factors Phase 4
16 Immunosuppressive Agents Phase 4
17 Anti-Inflammatory Agents Phase 4
18 glucocorticoids Phase 4
19 triamcinolone acetonide Phase 4
20 Triamcinolone diacetate Phase 4
21 Triamcinolone hexacetonide Phase 4
22 Antihypertensive Agents Phase 4
23 Mineralocorticoids Phase 4
24 Natriuretic Agents Phase 4
25 Mineralocorticoid Receptor Antagonists Phase 4
26 diuretics Phase 4
27 Diuretics, Potassium Sparing Phase 4
28 Pharmaceutical Solutions Phase 4
29
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
30
leucovorin Approved Phase 2 58-05-9 6006 143
31
Zinc Approved, Investigational Phase 2 7440-66-6 32051
32
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
33
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
34
Copper Approved, Investigational Phase 2 7440-50-8 27099
35
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
36
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
37
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
38
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
41
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
42
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
43
Spironolactone Approved Phase 1, Phase 2 1952-01-7, 52-01-7 5833
44
Brinzolamide Approved Phase 2 138890-62-7 68844
45
Finasteride Approved Phase 2 98319-26-7 57363
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
Lutein Approved, Investigational, Nutraceutical Phase 2 127-40-2 6433159
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
49
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
50
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4 Inspra (eplerenone)
2 A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy Completed NCT01574430 Phase 4
3 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
4 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
5 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
6 Clinical Outcomes Following Randomization of Steroid Concentration in Patients With Glenohumeral Osteoarthritis Recruiting NCT03586687 Phase 4 Triamcinolone
7 Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial) Active, not recruiting NCT03079141 Phase 4 Eplerenone
8 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
9 Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Unknown status NCT00418431 Phase 2, Phase 3 Intravitreal injection of Bevacizumab
10 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
11 A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy Completed NCT02735213 Phase 2, Phase 3
12 Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT02153125 Phase 2 Eplerenone
13 Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy Unknown status NCT01633983 Phase 2 Methotrexate;Delayed treatment
14 Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study Completed NCT01710332 Phase 2 Intravitreal Aflibercept Injection
15 Eplerenone for Central Serous Chorioretinopathy: A Pilot Study Completed NCT01822561 Phase 2 Eplerenone 50mg
16 High-dose Antioxidants for Central Serous Chorioretinopathy Completed NCT00963131 Phase 2 antioxidants tablets
17 Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR) Completed NCT00817245 Phase 1, Phase 2 omeprazole, Amoxicillin, metronidazole
18 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT00837252 Phase 1, Phase 2 Finasteride
19 A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole. Completed NCT00211393 Phase 2 ketoconazole
20 Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate Completed NCT00489840 Phase 1, Phase 2 Anecortave Acetate Sterile suspension 15 mg;Anecortave Acetate
21 Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01325181 Phase 1, Phase 2 Verteporfin;ranibizumab
22 Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC) Completed NCT02354170 Phase 2 Mifepristone;Placebo
23 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
24 Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial Completed NCT00987077 Phase 2
25 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
26 Pilot Phase I/II Study of the Treatment of Classic Central Serous Chorioretinopathy With Topical Interferon Gamma-1b Completed NCT01468337 Phase 1, Phase 2 Interferon gamma-1b
27 Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Completed NCT00211445 Phase 2 verteporfin
28 Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois Completed NCT01552044 Phase 1, Phase 2 Spironolactone;Placebo
29 Phase 2 Study of Non-damaging Retinal Laser Therapy Using PASCAL Laser With Endpoint Management Software for Macular Diseases Recruiting NCT01975103 Phase 2
30 Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy Not yet recruiting NCT03542006 Phase 2 Brinzolamide Ophthalmic
31 Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Terminated NCT01585441 Phase 2 Finasteride;Placebo
32 Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid. Completed NCT00403325 Phase 1 rhuFab V2 [ranibizumab] ( Lucentis )
33 Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy Completed NCT02036632 Phase 1
34 Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120636 Phase 1 Episcleral Celecoxib
35 Phase I Study of Sequestered Transscleral, Controlled-Release Dexamethasone Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120311 Phase 1 Episcleral Dexamethasone
36 Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab Unknown status NCT00864773
37 Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy Unknown status NCT02815176
38 The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Unknown status NCT01630863
39 Pseudo-PDT in Central Serous Chorioretinopathy Unknown status NCT02799992
40 Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease Unknown status NCT02443129
41 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884
42 Eplerenone for the Treatment of Central Serous Chorioretinopathy Completed NCT01990677 25mg Eplerenone;Placebo
43 Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology Completed NCT01610804
44 Persona of Central Serous Chorioretinopathy Completed NCT02819622
45 Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy Completed NCT03497000
46 Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis Completed NCT01378130
47 Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Completed NCT01434095
48 Comparison of Multifocal Electroretinogram Assessment Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Completed NCT00803517
49 Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography Completed NCT01327170
50 Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Completed NCT01019668 Verteporfin PDT, half-dose;verteporfin PDT, half-fluence

Search NIH Clinical Center for Central Serous Chorioretinopathy

Genetic Tests for Central Serous Chorioretinopathy

Anatomical Context for Central Serous Chorioretinopathy

MalaCards organs/tissues related to Central Serous Chorioretinopathy:

40
Eye, Retina, Bone, Bone Marrow, Brain, Endothelial, Heart

Publications for Central Serous Chorioretinopathy

Articles related to Central Serous Chorioretinopathy:

(show top 50) (show all 1897)
# Title Authors PMID Year
1
Solar retinal phototoxicity masquerading as self-inflicted handheld laser-induced lesions. 61
31909293 2020
2
Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. 61
31079056 2020
3
Three-dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography. 61
31724090 2020
4
Nanoencapsulation of synergistic antioxidant fruit and vegetable concentrates and their stability during in vitro digestion. 61
31650546 2020
5
Bioadsorbents from algae residues for heavy metal ions adsorption: chemical modification, adsorption behavior and mechanism. 61
31996100 2020
6
Correlation of retinal changes with choroidal changes in acute and recurrent central serous chorioretinopathy assessed by swept-source optical coherence tomography. 61
32010882 2020
7
Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy. 61
31929582 2020
8
Comment on: van Rijssen TJ, van Dijk EHC, Scholz P, et al. Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. 61
32000971 2020
9
MULTIPLE SEROUS PIGMENT EPITHELIAL DETACHMENTS IN ASSOCIATION WITH MAJOR WEIGHT LOSS: CASE REPORT AND REVIEW OF THE LITERATURE. 61
28834921 2020
10
Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats. 61
31751144 2020
11
Relapsing Pigment Epithelial Detachment in Central Serous Chorioretinopathy After Dilated Eye Examination. 61
31999295 2020
12
Eplerenone is not superior to placebo for chronic central serous chorioretinopathy. 61
31982052 2020
13
Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort. 61
31856486 2020
14
Commentary: Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort. 61
31856488 2020
15
Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy. 61
31863228 2020
16
Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy. 61
31925659 2020
17
CHANGES IN CHORIOCAPILLARIS, SATTLER, AND HALLER LAYER THICKNESSES IN CENTRAL SEROUS CHORIORETINOPATHY AFTER HALF-FLUENCE PHOTODYNAMIC THERAPY. 61
31985718 2020
18
Quantitative Assessment of Retinal Capillary Vessel Density and Foveal Avascular Zone Area in Central Serous Chorioretinopathy Using OCTA. 61
31962342 2020
19
Axial length as a basic anatomical predictor for morphological and clinical characteristics in acute central serous chorioretinopathy. 61
31969681 2020
20
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. 61
31982075 2020
21
Bilateral and multifocal central serous chorioretinopathy after injecting triamcinolone into a chalazion. 61
32001028 2020
22
Subretinal hyperreflective material in central serous chorioretinopathy. 61
31856489 2020
23
Response to comments on: Clinical profile of uveitis patients developing central serous chorioretinopathy - An experience at a tertiary eye care center in India. 61
31856557 2020
24
OCTA characterisation of microvascular retinal alterations in patients with central serous chorioretinopathy. 61
31949095 2020
25
Abnormal retrobulbar blood flow variables in central serous chorioretinopathy. 61
31943277 2020
26
Corticosteroids usage and central serous chorioretinopathy: a meta-analysis. 61
31734720 2020
27
Multimodal Imaging in Fibrinous Central Serous Chorioretinopathy Compared with Exudative Maculopathy. 61
32008002 2020
28
Association of Irregular Pigment Epithelial Detachment in Central Serous Chorioretinopathy with Genetic Variants Implicated in Age-related Macular Degeneration. 61
31988359 2020
29
Comparison of OCT and OCTA manifestations among untreated PCV, neovascular AMD, and CSC in Chinese population. 61
31956576 2020
30
Curcumin-Based Treatment for Macular Edema from Uncommon Etiologies: Efficacy and Safety Assessment. 61
31913752 2020
31
A rare case of diabetic macular edema with a central serous chorioretinopathy presenting as pseudohypopyon over macula. 61
31856512 2020
32
Severe proteinuria as a parameter of worse perinatal/neonatal outcomes in women with preeclampsia. 61
31972468 2020
33
The Correlation of Central Serous Chorioretinopathy and Subsequent Cardiovascular Diseases of Different Types: A Population-Based Cohort Study. 61
31847232 2019
34
Retinal pigment epithelium apertures as a late complication of longstanding serous pigment epithelium detachments in chronic central serous chorioretinopathy. 61
31267093 2019
35
Differential flow signal strength of choroidal neovascular membrane on optical coherence tomography angiography in central serous chorioretinopathy. 61
31806631 2019
36
Diurnal trajectories of salivary cortisol and α-amylase and psychological profiles in patients with central serous chorioretinopathy. 61
31842621 2019
37
Comparison of Half-Time and Half-Irradiance Photodynamic Therapy in Nonresolving Central Serous Chorioretinopathy. 61
31825265 2019
38
Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy. 61
31877221 2019
39
Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy. 61
31844791 2019
40
An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study. 61
31808315 2019
41
Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. 61
31833247 2019
42
GENETIC RISK FACTORS IN SEVERE, NONSEVERE AND ACUTE PHENOTYPES OF CENTRAL SEROUS CHORIORETINOPATHY. 61
31815877 2019
43
Large choroidal excavation in pachychoroid disease: A case report. 61
31801362 2019
44
Longitudinal Analysis of the Choriocapillaris Using Optical Coherence Tomography Angiography Reveals Subretinal Fluid as a Substantial Confounder in Patients with Acute Central Serous Chorioretinopathy. 61
31654333 2019
45
Bilateral diffuse uveal melanocytic proliferation secondary to thyroid carcinoma. 61
31755473 2019
46
A Novel Method for Detection and Progress Assessment of Visual Distortion Caused by Macular Disorder: A Central Serous Chorioretinopathy (CSR) Case Study. 61
31835894 2019
47
Choroidal binarization analysis: clinical application. 61
31140022 2019
48
Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy. 61
31925308 2019
49
CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. 61
31815880 2019
50
Bilateral serous retinal detachment associated with subretinal fibrin-like material in a case of pregnancy-induced hypertension. 61
31788578 2019

Variations for Central Serous Chorioretinopathy

Expression for Central Serous Chorioretinopathy

Search GEO for disease gene expression data for Central Serous Chorioretinopathy.

Pathways for Central Serous Chorioretinopathy

Pathways related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.09 SERPINE1 PLAT CFH C4B
2 10.94 SERPINE1 PLAT
3 10.07 SERPINE1 PLAT

GO Terms for Central Serous Chorioretinopathy

Cellular components related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.02 SLC7A5 SERPINE1 PLAT CFH C4B

Biological processes related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 8.62 SERPINE1 PLAT

Sources for Central Serous Chorioretinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....